Sectors
MCRB
Seres Therapeutics, Inc.
4.91
2 x 3.61
2 x 6.33
bid
ask
-
0.20
3.91%
2 @ 04:00 PM
4.91 +0.00 (0.00%)
| Ytd | -67.00% | |
| 1y | -74.08% |
4.91
day range
5.10
4.32
52 week range
29.98
| Open | 5.10 | Prev Close | 5.11 | Low | 4.91 | High | 5.10 | Mkt Cap | 49.32M |
| Vol | 44.23K | Avg Vol | 92.34K | EPS | -2.42 | P/E | N/A | Forward P/E | -1.75 |
| Beta | 0.20 | Short Ratio | 5.18 | Inst. Own | 37.15% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-04 | 50-d Avg | 5.61 | 200-d Avg | 10.05 | 1yr Est | 3.87 |
| Income Statement | |||
| Total Revenue | 736.00K | ||
| Revenues (USD) | 736.00K | ||
| Gross Profit | 736.00K | ||
| Operating Expenses | 22.01M | ||
| Research and Development Expense | 9.14M | ||
| Selling, General and Administrative Expense | 7.06M | ||
| Operating Income | -21.27M | ||
| Net Income | 4.58M | ||
| Net Income Common Stock | 4.58M | ||
| Net Income Common Stock (USD) | 4.58M | ||
| Consolidated Income | 4.58M | ||
| Earnings per Basic Share | 0.47 | ||
| Earnings per Basic Share (USD) | 0.47 | ||
| Earnings per Diluted Share | 0.47 | ||
| Earning Before Interest & Taxes (EBIT) | 4.58M | ||
| Earning Before Interest & Taxes (USD) | 4.58M | ||
| Weighted Average Shares | 9.71M | ||
| Weighted Average Shares Diluted | 9.75M | ||
| Balance Sheet | |||
| Cash and Equivalents | 17.84M | ||
| Cash and Equivalents (USD) | 17.84M | ||
| Trade and Non-Trade Receivables | 25.27M | ||
| Current Assets | 42.35M | ||
| Property, Plant & Equipment Net | 56.97M | ||
| Total Assets | 101.59M | ||
| Debt Current | 11.83M | ||
| Total Debt | 56.64M | ||
| Current Liabilities | 20.03M | ||
| Debt Non-Current | 44.82M | ||
| Total Liabilities | 67.05M | ||
| Accumulated Retained Earnings (Deficit) | -987.73M | ||
| Shareholders Equity | 34.53M | ||
| Shareholders Equity (USD) | 34.53M | ||
| Assets Non-Current | 59.24M | ||
| Total Debt (USD) | 56.64M | ||
| Liabilities Non-Current | 47.02M | ||
| Trade and Non-Trade Payables | 1.19M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 2.62M | ||
| Net Cash Flow from Financing | 1.72M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -20.66M | ||
| Capital Expenditure | 14.00K | ||
| Issuance (Purchase) of Equity Shares | 1.72M | ||
| Net Cash Flow from Investing | 14.00K | ||
| Net Cash Flow from Operations | -22.39M | ||
| Share Based Compensation | 1.74M | ||